David Tyrrell - Burcon NutraScience Independent Chairman of the Board

BU Stock  CAD 0.09  0.01  5.56%   

Chairman

Dr. David Lorne John Tyrrell, M.D. Ph.D. is Chairman of the Board of the Company. He is the Canadian Institute of Health Research Glaxo SmithKline Chair in Virology in the Department of Medical Microbiology and Immunology at the University of Alberta. Since 1986, he has focused his research on viral hepatitis. Supported by CIHR and Glaxo Canada, Dr. Tyrrells work on the development of antiviral therapy resulted in the licensing of the first oral antiviral agent to treat chronic hepatitis B infection lamivudine in 1998. Dr. Tyrrell holds 28 international patents for his studies on viral hepatitis. Dr. Tyrrell was Dean of the Faculty of Medicine and Dentistry from 1994 2004 at the University of Alberta and is currently the Chair of the Board of Directors of the Gairdner Foundation. The Canada Gairdner International Awards recognizes excellence in medical science research globally. Dr. Tyrrell has received numerous prestigious awards including the Gold Medal of the Canadian Liver Foundation, the FNG Starr Award of the Canadian Medical Association and the Principal Award of the Manning Awards Foundation since 2019.
Age 66
Tenure 5 years
Professional MarksPh.D
Address 1946 West Broadway, Vancouver, BC, Canada, V6J 1Z2
Phone604 733 0896
Webhttps://www.burcon.ca
Tyrrell was appointed Officer of the Order of Canada in 2002. In April 2010, D. Lorne Tyrrell was appointed as the inaugural director of the Li Ka Shing Institute of Virology at the University of Alberta. On April 28, 2011, Dr. Tyrrell was inducted to the Canadian Medical Hall of Fame.

Burcon NutraScience Management Efficiency

The company has return on total asset (ROA) of (0.3922) % which means that it has lost $0.3922 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.5936) %, meaning that it generated substantial loss on money invested by shareholders. Burcon NutraScience's management efficiency ratios could be used to measure how well Burcon NutraScience manages its routine affairs as well as how well it operates its assets and liabilities. As of the 11th of December 2024, Return On Tangible Assets is likely to drop to -0.67. In addition to that, Return On Capital Employed is likely to drop to -0.64. At this time, Burcon NutraScience's Non Currrent Assets Other are very stable compared to the past year. As of the 11th of December 2024, Other Current Assets is likely to grow to about 826.5 K, while Total Assets are likely to drop about 10.9 M.
Burcon NutraScience has accumulated 6.67 M in total debt with debt to equity ratio (D/E) of 0.28, which may suggest the company is not taking enough advantage from borrowing. Burcon NutraScience has a current ratio of 10.55, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Burcon NutraScience until it has trouble settling it off, either with new capital or with free cash flow. So, Burcon NutraScience's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Burcon NutraScience sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Burcon to invest in growth at high rates of return. When we think about Burcon NutraScience's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 2 records

CHAIRMAN Age

Randy DeweyBaylin Technologies
47
Jeffrey RoyerBaylin Technologies
63
Burcon NutraScience Corporation, together with its subsidiary, develops plant proteins and ingredients for use in the food and beverage industries in Canada. Burcon NutraScience Corporation was founded in 1998 and is headquartered in Vancouver, Canada. BURCON NUTRASCIENCE operates under Packaged Foods classification in Canada and is traded on Toronto Stock Exchange. It employs 21 people. Burcon NutraScience (BU) is traded on Toronto Exchange in Canada and employs 25 people. Burcon NutraScience is listed under Packaged Foods & Meats category by Fama And French industry classification.

Management Performance

Burcon NutraScience Leadership Team

Elected by the shareholders, the Burcon NutraScience's board of directors comprises two types of representatives: Burcon NutraScience inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Burcon. The board's role is to monitor Burcon NutraScience's management team and ensure that shareholders' interests are well served. Burcon NutraScience's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Burcon NutraScience's outside directors are responsible for providing unbiased perspectives on the board's policies.
Randy Willardsen, Senior Vice President - Process
Johann Tergesen, President, Chief Executive Officer, Chief Operating Officer
Paul Lam, Director Relations
Kip MBA, Chief Officer
Dorothy Law, Senior Vice President - Legal, Corporate Secretary
Peter Kappel, Independent Director
Alan Chan, Independent Director
Debora Fang, Independent Director
MBA CFA, Chief Officer
Bradford Allen, Lead Independent Director
David Ju, Independent Director
Chi Ng, Director
John Gilpin, Independent Director
Martin Schweizer, Vice President - Technical Development
Kam Law, Senior Secretary
Rosanna Chau, Director
David Tyrrell, Independent Chairman of the Board
Jade Cheng, Chief Financial Officer, Treasurer
Calvin Ng, Director

Burcon Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Burcon NutraScience a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Other Information on Investing in Burcon Stock

Burcon NutraScience financial ratios help investors to determine whether Burcon Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Burcon with respect to the benefits of owning Burcon NutraScience security.